Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 233 for “"Imatinib"”.
-
Impact of CYP2C8 single nucleotide polymorphisms on in-vitro metabolism of imatinib to N-desmethyl imatinib
Imatinib is a first line therapy for the treatment of chronic myeloid leukaemia (CML). Treatment with imatinib must be continuous and indefinite for most patients to maintain disease control. Despite excellent efficacy and tolerability, up to 50% of CML patients discontinue imatinib due to lack of …
-
Mutationsanalyse von Tyrosinkinasen bei Imatinib-sensiblen Weichteilsarkomen
… stellt der spezifische Tyrosinkinaseinhibitor Imatinib/ STI571 (Glivec®) durch Blockade der pathologischen Signaltransduktion eine zielgerichtete molekulare Therapiemodalität mit hoher Effektivität bei einem vergleichsweise insgesamt geringen Nebenwirkungsspektrum dar. <br>In der vorliegenden …
-
Einfluss des Tyrosinkinase-Inhibitors Imatinib auf Ewing-Sarkom-Zellen in vitro : Untersuchung mit Imatinib allein und in Kombination mit Standard-Zytostatika
… zu untersuchen, ob der Tyrosinkinase-Inhibitor Imatinib das Wachstumsverhalten von Ewing-Sarkom-Zelllinien beeinflussen kann. <br>Dazu wurden 8 Ewing-Sarkom-Zelllinien im Durchflußzytometer auf die Expression von c-Kit, PDGFR-alpha; und PDGFR-ß untersucht. Diese drei Rezeptoren gelten als …
-
Minimal residual disease in chronic myeloid leukaemia after imatinib treatment.
… myeloid leukaemia (CML) patients who remain on imatinib treatment for more than 5 years will achieve a complete molecular response (CMR), defined by undetectable BCR-ABL mRNA in a sensitive reverse transcriptase real-time quantitative PCR (RQ-PCR) assay. Given the increasing importance of CMR on …
-
MECHANISTIC STUDIES ON THE PHOTOTOXICITY OF ROSUVASTATIN, ITRACONAZOLE AND IMATINIB
… to proteins. In chapter 5, photobehavior of imatinib (IMT) was addressed. This is a promising tyrosine kinase inhibitor used in the treatment of some types of human cancer, which constitutes a successful example of rational drug design based on the optimization of the chemical structure to …
-
Modeling Imatinib-Treated Chronic Myelogenous Leukemia and the Immune System
Chronic myelogenous leukemia can be considered as a chronic condition thanks to the development of tyrosine kinase inhibitors in the early 2000s. Most CML patients are able to manage the disease, but unending treatment can affect quality of life. The focus of much clinical research has thus …
-
Long-term effects of imatinib on cognition in chronic myeloid leukaemia
Imatinib was successfully introduced into haematology-oncology practice in 2001 and rapidly endorsed as a first line treatment for chronic myeloid leukaemia (CML) in the chronic, accelerated, and blastic phases. The survival advantage demonstrated by this target kinase inhibitor has meant that …
-
Bim Mediates Imatinib-Induced Apoptosis of Gastrointestinal Stromal Tumors: Translational Implications
… receptor tyrosine kinases KIT and PDGFR-α. Imatinib mesylate, a specific inhibitor of KIT and PDGFR-α signaling, delays progression of GIST, but is incapable of achieving cure. Thus, most patients who initially respond to imatinib therapy eventually experience tumor progression, and have …
-
Identifizierung und funktionelle Charakterisierung von microRNAs bei Imatinib-Therapieresistenz der CML
… von Resistenzen 30 % der Patient*innen nicht auf Imatinib an. Ursächlich für diese ist unter anderem die Resistenzbildung durch kleine nichtkodierende microRNAs. Obwohl eine Vielzahl von microRNAs in verschiedenen Erkrankungen als Biomarker vorgeschlagen wurde, steht ihre Implementierung als …
-
The Effects of Imatinib Mesylate on Antigen-Specific Cd8+ T Cell Responses
Imatinib mesylate (IM) is a chemical compound designed to inhibit the constitutive tyrosine kinase activity of the Bcr-Abl oncogene in Chronic Myelogenous Leukemia (CML). While IM is very potent in treating CML, little is understood concerning the effects of IM on the immune response. In this …
-
Defining CP-CML patient subsets associated with poor imatinib uptake and response.
… kinase inhibitor (TKI) therapy, specifically imatinib, has dramatically improved the treatment outcome for the majority of chronic phase chronic myeloid leukaemia (CP-CML) patients. Although most patients will achieve excellent clinical (haematological, cytogenetic and molecular) responses on …
-
Epigenetische Mechanismen der Imatinib-Resistenz in der Behandlung der Chronischen Myeloischen Leukämie
… guter Erfolge mit dem Tyrosinkinaseinhibitor Imatinib in der Behandlung der CML wird bei einem relevanten Anteil der Patienten eine Resistenzbildung beobachtet. Ein möglicher Resistenzmechanismus postuliert eine veränderte Expression von Schlüsselgenen in krebsassoziierten …
-
GM-CSF protection of CML CD34+ cells from the inhibitory effect of imatinib.
… of chronic myeloid leukemia progenitors to imatinib. In addition it was aimed to examine CML cell production of GM-CSF. Findings suggest that non-CD34+ cells may be a source of GM-CSF.
-
Haemopoiesis, leukaemia & imatinib: c-fms, a novel target for small molecule inhibitor therapy.
… not CML cells. The tyrosine kinase inhibitor, imatinib, is a novel drug displaying promising results in the treatment of CML by specifically inhibiting the growth of leukaemic cells. To examine whether myelosuppression observed in patients treated with imatinib may arise from inhibition of …
-
In vitro Untersuchungen von Therapiekombinationen mit Chemotherapeutika und dem Tyrosinkinaseinhibitor Imatinib am Mammakarzinom
Der Tyrosinkinaseinhibitor Imatinib Mesylat ist ein Medikament zur Behandlung der Chronisch myeloischen Leukämie (CML), von gastointestinalen Stromatumoren (GIST) sowie anderen malignen Erkrankungen. Die Wirkung von Imatinib wird durch eine kompetitive und selektive Blockade der ATP-Bindungsstelle …
-
Patient Characteristics and Outcomes of Gastrointestinal Stromal Tumor Patients Undergoing Imatinib Plasma Level Testing
… stromal tumor (GIST) is effectively treated with imatinib, there are a number of clinical challenges in the optimal treatment of these patients. The plasma steady-state trough level of imatinib has been proposed to correlate with clinical outcome. Plasma imatinib level may be affected by a number …
Page 1 of 12